BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $87.95, for a total transaction of $703,600.00. Following the completion of the sale, the chief executive officer now owns 335,530 shares of the company’s stock, valued at approximately $29,509,863.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Tuesday, January 7th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.46, for a total transaction of $253,380.00.
- On Friday, December 27th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00.
- On Friday, November 22nd, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $77.60, for a total transaction of $776,000.00.
- On Friday, October 25th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $69.55, for a total transaction of $347,750.00.
Shares of NASDAQ:BMRN traded down $2.30 during trading on Friday, reaching $86.57. The company had a trading volume of 1,211,654 shares, compared to its average volume of 1,256,267. The firm’s fifty day moving average is $86.34 and its 200 day moving average is $77.74. The firm has a market capitalization of $15.96 billion, a PE ratio of -332.96 and a beta of 1.39. BioMarin Pharmaceutical Inc. has a twelve month low of $62.88 and a twelve month high of $96.85. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.53 and a current ratio of 3.77.
Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of BioMarin Pharmaceutical by 154.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,741 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 1,057 shares in the last quarter. National Pension Service lifted its holdings in BioMarin Pharmaceutical by 6.5% in the 2nd quarter. National Pension Service now owns 220,894 shares of the biotechnology company’s stock worth $18,920,000 after buying an additional 13,432 shares in the last quarter. Vanguard Group Inc. lifted its holdings in BioMarin Pharmaceutical by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 15,957,672 shares of the biotechnology company’s stock worth $1,366,775,000 after buying an additional 247,798 shares in the last quarter. Marshall Wace North America L.P. lifted its holdings in BioMarin Pharmaceutical by 33.4% in the 2nd quarter. Marshall Wace North America L.P. now owns 540,205 shares of the biotechnology company’s stock worth $46,270,000 after buying an additional 135,130 shares in the last quarter. Finally, Worth Venture Partners LLC lifted its holdings in BioMarin Pharmaceutical by 1.9% in the 2nd quarter. Worth Venture Partners LLC now owns 27,300 shares of the biotechnology company’s stock worth $2,339,000 after buying an additional 511 shares in the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.
BMRN has been the subject of a number of recent research reports. Barclays raised shares of BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $86.00 to $98.00 in a research note on Wednesday, November 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $129.00 target price on shares of BioMarin Pharmaceutical in a research note on Monday, December 16th. Cowen reaffirmed a “buy” rating and issued a $150.00 target price on shares of BioMarin Pharmaceutical in a research note on Monday, December 16th. BidaskClub raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Bank of America reiterated a “buy” rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $110.67.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Story: What is a Tariff?
Receive News & Ratings for BioMarin Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
